Conditions

This post was originally published on this site The European Commission (EC) has approved a combination regimen of Bavencio (avelumab) injections plus Inlyta (axitinib) tablets for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC), the most common type of kidney cancer. The combination can be used in patients regardless of their predicted…

This post was originally published on this site The U.S. Food and Drug Administration (FDA) has granted its Regenerative Medicine Advanced Therapy (RMAT) designation to the investigational therapy CT053 for the treatment of relapsed or refractory multiple myeloma. The RMAT designation is given to regenerative therapies intended to treat, modify, reverse, or cure a serious…

This post was originally published on this site Adding Lynparza (olaparib) to Avastin (bevacizumab) as a first-line maintenance treatment significantly delayed disease progression in women with advanced ovarian cancer — regardless of BRCA mutation status — interim data from a Phase 3 study show. This maintenance therapy was given after partial or complete response to first-line platinum-based chemotherapy. The…

This post was originally published on this site In a lighthearted twist on a serious goal of raising awareness and funds for prostate cancer, the Movember Foundation is again encouraging gents to join glitterati in celebrating the moustache. The annual event is called Movember, a blending of the Australian-English “mo” for moustache with “November,” the month…

This post was originally published on this site A Phase 1/2 trial assessing Oncternal Therapeutics‘ cirmtuzumab plus Imbruvica (ibrutinib) for the treatment of B-cell cancers is opening a Phase 1b extension part to continue studying the combination in people with mantle cell lymphoma (MCL), the company announced. The expansion was based on positive interim results from…

This post was originally published on this site Implementation of routine tumor genetic testing may help identify the approximately 30% of men with metastatic castration-resistant prostate cancer (mCRPC) who may significantly benefit from targeted treatment, namely PARP inhibitors, an international study suggests. The results were presented in a poster, titled “Central, prospective detection of homologous…

This post was originally published on this site Massachusetts pathologist Lija Joseph, MD, has created an innovative program that allows patients, including those with breast cancer, to actually see the cells that make up their malignancies. In doing so, the hope is that patients will gain the understanding, strength, and knowledge that will help them…

This post was originally published on this site Copiktra (duvelisib), developed by Verastem Oncology, may be an effective and reasonably safe treatment option for people with marginal zone lymphoma who failed to respond to prior therapies including rituximab, Phase 2 data show. The findings were presented at the Lymphoma & Myeloma 2019 International Congress, held Oct. 23-26 in New…

This post was originally published on this site With the goal of encouraging the multiple myeloma community while raising money to advance treatments, Moving Mountains for Multiple Myeloma (MM4MM) is gearing up for its next expedition — Patagonia. The Nov. 9–19 excursion will take participants across the picturesque, but often-rugged, terrain of the region at the southern end of…

This post was originally published on this site Taking Zejula (niraparib) as a maintenance therapy may increase time without symptoms or toxicities from treatment in women with recurrent ovarian cancer, a new study found. These results suggest that Zejula could increase quality of life in addition to slowing cancer growth. The study, “Niraparib Maintenance Treatment…